Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03587194 · ClinicalTrials.gov registry record · Phase 4

Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis

A Phase 4 study, sponsored by Psoriasis Treatment Center of Central New Jersey.

Completed
Registry status
Phase 4
Development phase
50
Enrollment target

NCT03587194 is a Phase 4 study that has completed, run by Psoriasis Treatment Center of Central New Jersey. The registered enrollment target is 50 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03587194, a Phase 4 study, has completed, sponsored by Psoriasis Treatment Center of Central New Jersey.

COMPLETED
Registry status
Phase 4
Development phase
50 participants
Enrollment target

Study Summary

Add-on Enstilar to Otezla therapy.

Interventions

  • DRUG Otezla

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2018-07-23
Est. Completion 2019-07-01
Phase Phase 4

What the Registry Record Tells You About NCT03587194

The ClinicalTrials.gov registry entry for NCT03587194 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Psoriasis Treatment Center of Central New Jersey, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Otezla is the first listed.

NCT03587194 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03587194 about?

NCT03587194 is a clinical study titled "Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis". Add-on Enstilar to Otezla therapy.

What is the current status of trial NCT03587194?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2018-07-23. Estimated completion is 2019-07-01.

What interventions are being tested in trial NCT03587194?

The interventions under investigation include: Otezla (DRUG).

Who is sponsoring clinical trial NCT03587194?

This trial is sponsored by Psoriasis Treatment Center of Central New Jersey, which has 16 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.